JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanagy, N. L.
Right arrow Articles by Fink, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanagy, N. L.
Right arrow Articles by Fink, G. D.

Losartan prevents salt-induced hypertension in reduced renal mass rats

NL Kanagy and GD Fink

Department of Pharmacology and Toxicology, Michigan State University, East Lansing.

A reduction in functioning renal mass through surgical ablation leads to the development of hypertension and chronic renal failure in rats. Reduced renal mass (RRM) hypertension is more severe and develops more quickly if rats are on high salt intake. It has previously been shown that hypertension in these rats can be prevented by treatment with angiotensin-converting enzyme inhibitors. The current experiment examined the effect of losartan, an angiotensin II antagonist, on blood pressure in RRM and intact rats after a 3-fold increase in salt intake. It was found that chronic treatment with i.v. losartan (3 mg/kg/day) completely prevented sodium-induced hypertension in the RRM rats, whereas neither increased salt intake nor losartan treatment affected blood pressure in the intact rats. The antihypertensive effect of losartan was associated with an apparent renoprotective effect in RRM rats (blood urea nitrogen concentration rose in untreated animals, but remained stable in treated animals), but was not accompanied by chronic changes in water or sodium balance. The ability of losartan to prevent RRM hypertension suggests that angiotensin II is necessary for the development of this model of hypertension.

Volume 265, Issue 3, pp. 1131-1136, 06/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. F. Reckelhoff and J. C. Romero
Role of oxidative stress in angiotensin-induced hypertension
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
N. L. Kanagy, B. R. Walker, and L. D. Nelin
Role of Endothelin in Intermittent Hypoxia-Induced Hypertension
Hypertension, February 1, 2001; 37(2): 511 - 515.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. J. Rieder, R. J. Roman, and A. S. Greene
Reversal of Microvascular Rarefaction and Reduced Renal Mass Hypertension
Hypertension, July 1, 1997; 30(1): 120 - 127.
[Abstract] [Full Text]

Home page
 HypertensionHome page
D. H. Wang, A. Yao, H. Zhao, and D. J. DiPette
Distinct Mechanisms of Modulation of Angiotensin II Type I Receptor Gene Expression in Heart and Aorta
Hypertension, May 1, 1997; 29(5): 1104 - 1108.
[Abstract] [Full Text]

Home page
 HypertensionHome page
F. Elijovich, H.-W. Zhao, C. L. Laffer, Y. Du, D. J. DiPette, T. Inagami, and D. H. Wang
Regulation of Growth of the Adrenal Gland in DOC-Salt Hypertension: Role of Angiotensin II Receptor Subtypes
Hypertension, January 1, 1997; 29(1): 408 - 413.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.